Abstract
New evidence has dramatically demonstrated that only a minority of cancer cells has the capacity to proliferate extensively and form new tumors; these cells are called “tumor-initiating cells” or “cancer stem cells”. In this review, we focus on recent molecular insights into the nature of cancer stem cells in leukemia, leukemic stem cells (LSCs). LSCs arise not only from primitive hematopoietic stem cells (HSCs) with self-renewal capacity but also from committed progenitor cells that normally lack the ability to self-renew. These latter cells gain stem cell properties by reactivating a gene expression program similar to that functioning in normal HSCs. The self-renewal and differentiation capacities of normal primitive hematopoietic cells are controlled by complex signaling pathways involving Wnt/β-catenin, Pu.1/JunB and PI3K/Akt. These same mediators also participate in the leukemogenesis. In mice, administration of drugs such as rapamycin and anti-CD44 antibody, which target properties unique to LSCs, can selectively deplete these cells in vivo. The goal for this field is to design successful human leukemia therapies based on the targeting or manipulation of features specific to LSCs.
Keywords: Leukemic stem cells, hematopoietic stem cells, self-renewal capacity
Current Cancer Therapy Reviews
Title: The Molecular Bases of the Self-Renewal and Differentiation of Leukemic Stem Cells
Volume: 4 Issue: 3
Author(s): Kazuhito Naka, Masako Ohmura, Takayuki Hoshii, Teruyuki Muraguchi and Atsushi Hirao
Affiliation:
Keywords: Leukemic stem cells, hematopoietic stem cells, self-renewal capacity
Abstract: New evidence has dramatically demonstrated that only a minority of cancer cells has the capacity to proliferate extensively and form new tumors; these cells are called “tumor-initiating cells” or “cancer stem cells”. In this review, we focus on recent molecular insights into the nature of cancer stem cells in leukemia, leukemic stem cells (LSCs). LSCs arise not only from primitive hematopoietic stem cells (HSCs) with self-renewal capacity but also from committed progenitor cells that normally lack the ability to self-renew. These latter cells gain stem cell properties by reactivating a gene expression program similar to that functioning in normal HSCs. The self-renewal and differentiation capacities of normal primitive hematopoietic cells are controlled by complex signaling pathways involving Wnt/β-catenin, Pu.1/JunB and PI3K/Akt. These same mediators also participate in the leukemogenesis. In mice, administration of drugs such as rapamycin and anti-CD44 antibody, which target properties unique to LSCs, can selectively deplete these cells in vivo. The goal for this field is to design successful human leukemia therapies based on the targeting or manipulation of features specific to LSCs.
Export Options
About this article
Cite this article as:
Naka Kazuhito, Ohmura Masako, Hoshii Takayuki, Muraguchi Teruyuki and Hirao Atsushi, The Molecular Bases of the Self-Renewal and Differentiation of Leukemic Stem Cells, Current Cancer Therapy Reviews 2008; 4 (3) . https://dx.doi.org/10.2174/157339408785294267
DOI https://dx.doi.org/10.2174/157339408785294267 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Reduction in Ischemic Cerebral Infarction is Mediated through Golgi Phosphoprotein 3 and Akt/mTOR Signaling Following Salvianolate Administration
Current Neurovascular Research Development of Lymphatic Vessels: Tumour Lymphangiogenesis and Lymphatic Invasion
Current Medicinal Chemistry Novel Action and Mechanism of Auranofin in Inhibition of Vascular Endothelial Growth Factor Receptor-3-Dependent Lymphangiogenesis
Anti-Cancer Agents in Medicinal Chemistry New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors
Current Pharmaceutical Design Cytotoxicity of Novel Sulfanilamides Towards Sensitive and Multidrugresistant Leukemia Cells
Current Medicinal Chemistry MicroRNAs and Cancer; an Overview
Current Pharmaceutical Biotechnology Targeting Glioblastoma Stem Cells: Cell Surface Markers
Current Medicinal Chemistry Status of Flavonols as P-Glycoprotein Inhibitors in Cancer Chemotherapy
Current Cancer Therapy Reviews Peptide Vaccines for Cancer Therapy
Recent Patents on Inflammation & Allergy Drug Discovery Epigenetic Alterations of the Wnt/β -Catenin Pathway in Human Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Use of Molecules that Mimic Pathogen Danger Signals
Endocrine, Metabolic & Immune Disorders - Drug Targets Gamma-Oryzanol – A Multi-Purpose Steryl Ferulate
Current Nutrition & Food Science The Protein Profile of Fibroblasts: The Role of Proteomics
Current Proteomics Small Molecule Aurora Kinases Inhibitors
Current Medicinal Chemistry Gemcitabine: A Critical Nucleoside for Cancer Therapy
Current Medicinal Chemistry Modulation of Ornithine Decarboxylase Activity by Phenolics Based Structurally Related Compounds Synthesized on Steroidal and Non-Steroidal Skeleton and their Radical Scavenging Action
Current Bioactive Compounds Natural Small Molecules as Stabilizers and Activators of Cancer-Associated NQO1 Polymorphisms
Current Drug Targets Recent Progress in the Development of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Review on Documented Medicinal Plants used for the Treatment of Cancer
Current Traditional Medicine